AstraZeneca Provides Update on P-III (KOMET) Study of Koselugo for Treating Neurofibromatosis Type 1
Shots:
- The P-III (KOMET) study assessed the efficacy & safety of Koselugo (jointly developed with Merck) vs PBO in 145 adults with NF1 and symptomatic, inoperable PNs across 13 countries incl. North America, South America, Europe, Asia & Australia
- Study achieved its 1EP, significantly improving the objective response rate (ORR) in adults with NF1 and symptomatic, inoperable plexiform neurofibromas
- The safety profile aligned with previous studies in children and adolescents, with no new safety concerns. Alexion (AZ Rare Disease) will share the data with regulators and highlight it at future conferences
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca’s Fasenra Receives EU Approval for Eosinophilic Granulomatosis with Polyangiitis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
